Skip to content
2000
Volume 7, Issue 1
  • ISSN: 2666-7967
  • E-ISSN: 2666-7975

Abstract

Background

In December 2019, a group of patients in Wuhan, Hubei province, China, presented with severe illness and pneumonia of unknown origin. Subsequently, a novel coronavirus was identified as the cause and named “2019 novel coronavirus” (2019-nCoV), later defined as “SARS-CoV-2” (Severe Acute Respiratory Syndrome Coronavirus-2), leading to the development of the disease known as COVID-19. This study aimed to evaluate the effectiveness and safety of convalescent plasma as a potential therapy for patients with COVID-19.

Methods

Patients diagnosed with COVID-19 based on real-time polymerase chain reaction (PCR) or CT-Scan symptoms were randomly assigned to either the treatment group (n = 29, received convalescent plasma) or the control group (n = 29). Clinical manifestations and pulmonary involvement were monitored three times during the study. At the end of the intervention, patients were evaluated for clinical symptoms, laboratory test results, and length of hospital stay.

Results

Among the 58 patients who completed the study, there were no significant differences in baseline characteristics between the treatment and control groups upon admission to the hospital. However, the length of hospital stay was significantly shorter (9.54 days) in the convalescent plasma group compared to the control group (12.88 days).

Conclusion

The findings from this study indicate that the use of convalescent plasma therapy, in addition to standard treatment, did not result in reduced mortality or improved clinical outcomes at day 7 when compared to a placebo or control group.

Clinical Trial Registration Number

IRCT20210714051887N1.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/covid/10.2174/0126667975307584240927114217
2024-10-07
2026-02-25

  • From This Site

    /content/journals/covid/10.2174/0126667975307584240927114217
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. LuR. ZhaoX. LiJ. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding.Lancet20203951022456557410.1016/S0140‑6736(20)30251‑832007145
     [Google Scholar]
  2. CossarizzaA. De BiasiS. GuaraldiG. GirardisM. MussiniC. SARS‐CoV‐2, the virus that causes COVID‐19: Cytometry and the new challenge for global health.Cytometry A202097434034310.1002/cyto.a.2400232187834
     [Google Scholar]
  3. HuangC. WangY. LiX. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.Lancet20203951022349750610.1016/S0140‑6736(20)30183‑531986264
     [Google Scholar]
  4. AbolghasemiH. EshghiP. CheraghaliA.M. Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study.Transfus. Apheresis Sci.202059510287510.1016/j.transci.2020.10287532694043
     [Google Scholar]
  5. AbdiM. Coronavirus disease 2019 (COVID-19) outbreak in Iran: Actions and problems.Infect. Control Hosp. Epidemiol.202041675475510.1017/ice.2020.8632192541
     [Google Scholar]
  6. LasockaJ. BielawskiA. LachertE. Passive immunization in the combat against infectious diseases (COVID-19 included).J Transfus Med2021142505710.5603/JTM.2021.0004
     [Google Scholar]
  7. YoungM.K. CrippsA.W. Passive immunization for the public health control of communicable diseases: Current status in four high-income countries and where to next.Hum. Vaccin. Immunother.2013991885189310.4161/hv.2531123783220
     [Google Scholar]
  8. ZengH. WangD. NieJ. The efficacy assessment of convalescent plasma therapy for COVID-19 patients: A multi-center case series.Signal Transduct. Target. Ther.20205121910.1038/s41392‑020‑00329‑x33024082
     [Google Scholar]
  9. ChenL. XiongJ. BaoL. ShiY. Convalescent plasma as a potential therapy for COVID-19.Lancet Infect. Dis.202020439840010.1016/S1473‑3099(20)30141‑932113510
     [Google Scholar]
  10. ChengY. WongR. SooY.O.Y. Use of convalescent plasma therapy in SARS patients in Hong Kong.Eur. J. Clin. Microbiol. Infect. Dis.2005241444610.1007/s10096‑004‑1271‑915616839
     [Google Scholar]
  11. PanF. YeT. SunP. Time course of lung changes at chest CT during recovery from coronavirus disease 2019 (COVID-19).Radiology2020295371572110.1148/radiol.202020037032053470
     [Google Scholar]
  12. SooY.O.Y. ChengY. WongR. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients.Clin. Microbiol. Infect.200410767667810.1111/j.1469‑0691.2004.00956.x15214887
     [Google Scholar]
  13. LukeT.C. KilbaneE.M. JacksonJ.L. HoffmanS.L. Meta-analysis: Convalescent blood products for Spanish influenza pneumonia: A future H5N1 treatment?Ann. Intern. Med.2006145859960910.7326/0003‑4819‑145‑8‑200610170‑0013916940336
     [Google Scholar]
  14. ArabiY.M. HajeerA.H. LukeT. Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia.Emerg. Infect. Dis.20162291554156110.3201/eid2209.15116427532807
     [Google Scholar]
  15. DuanK. LiuB. LiC. Effectiveness of convalescent plasma therapy in severe COVID-19 patients.Proc. Natl. Acad. Sci. USA2020117179490949610.1073/pnas.200416811732253318
     [Google Scholar]
  16. Mair-JenkinsJ. Saavedra-CamposM. BaillieJ.K. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: A systematic review and exploratory meta-analysis.J. Infect. Dis.20152111809010.1093/infdis/jiu39625030060
     [Google Scholar]
  17. van GriensvenJ. EdwardsT. de LamballerieX. Evaluation of convalescent plasma for Ebola virus disease in Guinea.N. Engl. J. Med.20163741334210.1056/NEJMoa151181226735992
     [Google Scholar]
  18. SimonovichV.A. Burgos PratxL.D. ScibonaP. A randomized trial of convalescent plasma in Covid-19 severe pneumonia.N. Engl. J. Med.2021384761962910.1056/NEJMoa203130433232588
     [Google Scholar]
  19. AgarwalA. Convalescent plasma in the management of moderate COVID-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial).BMJ2020371
     [Google Scholar]
  20. LiuZ. Errors in trial of effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19.JAMA2020324551851910.1001/jama.2020.1260732749486
     [Google Scholar]
  21. LaingA.G. LorencA. del Molino del BarrioI. A dynamic COVID-19 immune signature includes associations with poor prognosis.Nat. Med.202026101623163510.1038/s41591‑020‑1038‑632807934
     [Google Scholar]
  22. BastardP. RosenL.B. ZhangQ. Autoantibodies against type I IFNs in patients with life-threatening COVID-19.Science20203706515eabd458510.1126/science.abd458532972996
     [Google Scholar]
/content/journals/covid/10.2174/0126667975307584240927114217
Loading
Exploring the Efficacy of Convalescent Plasma Therapy in COVID-19 Patients: A Clinical Trial Study
Coronaviruses 7, E26667975307584 (2026); https://doi.org/10.2174/0126667975307584240927114217
/content/journals/covid/10.2174/0126667975307584240927114217
/content/journals/covid/10.2174/0126667975307584240927114217
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): convalescent plasma; COVID-19; CT-Scan; patient; real-time PCR; Treatment

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test